On September 16th, the virtual ESMO Congress 2021 began. This week, we'll hear from the authors of three influential, late-breaking studies presented at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're hearing about three abstracts presented during the IASLC 2021 World Conference on Lung Cancer, focusing on clinical trial enrollment during the COVID-19 pandemic, air pollution's role in lung cancer risk, and strategies for reducing barriers and improving cancer care in low-resource areas. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're reviewing the details of Genentech's decision to withdraw atezolizumab's indication for metastatic triple-negative breast cancer. We'll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Coverage of stories discussed this week on ascopost.com: Update on U.S. Indication for Atezolizumab ...
This week, we'll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease. Coverage of stories discussed this week on ascopost.com: FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease To listen to more podcasts fr...
This week, we'll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we'll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy. Coverage of stories discussed this week on ascopost.com: Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers Outcomes With 2 vs 5 Y...
On this episode, we're hearing from experts presenting data on hematologic malignancies during the 2021 Pan Pacific Lymphoma Conference, which begins on August 9 and concludes on August 13. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Recently, The ASCO Post published an article titled 'Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to "cure" patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further. Coverage of stories discussed this week on ascopost.com: Defining C...
On this episode, we're reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We'll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer. Coverage of stories discussed this week on ascopost.com: Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer To listen to more ...
This week, we're reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we'll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers. Coverage of stories discussed this week on ascopost.com: FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer Mechanisms of Acquired Resistance to KRAS G12C I...
This week, we're discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival. Coverage of stories discussed this week on ascopost.com: Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer FDA A...
This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
This week marks our 100th episode of the podcast! We launched at the start of the 2019 ASCO Annual Meeting, and this week, we're reporting major findings from the 2021 Annual Meeting, including adjuvant therapy for patients with BRCA-mutated breast cancer, LuPSMA for metastatic prostate cancer, and an update on CodeBreak100, the trial that led to the recent FDA approval of sotorasib for KRAS G12C–mutated non–small cell lung cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
This week, we're discussing the recent U.S. Preventive Services Task Force, or USPSTF, recommendation on colorectal cancer screening beginning at 45. Then, we'll hear about a doublet regimen that produced durable responses in patients with advanced head and neck cancer. Lastly, we'll hear about a study being presented during the ASCO Annual Meeting about a novel immunotherapy combination for advanced melanoma. Coverage of stories discussed this week on ascopost.com: USPSTF Issues New Recommendat...
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed . On this podcast, we'll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of Medicaid expansion on long-term survival for patients with cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
We'll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we'll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic. Coverage of stories discussed this week on ascopost.com: Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer The COVID-19 Pandemi...
This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor. The Marshalls are the coauthors of a new book entitled Off Our Chests: A Candid Tour Through the World of Cancer , published this week by IdeaPress Publishing and named one of the "10 Books to Read in May 2021" by The Washington Post . Together, they discuss the impac...
This week, we'll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we'll talk about the FDA's approval of a new agent for advanced endometrial cancer. Coverage of stories discussed this week on ascopost.com: Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer To li...
This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We'll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer. Coverage of stories discussed this week on ascopost.com: Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy First-Line Tislelizumab Plus Chemotherapy vs Chemother...
On this week's podcast, we're continuing our coverage of the 2021 AACR Annual Meeting. We'll hear from researchers on the role of cancer biology in treatment paradigms; novel strategies in the care of patients with brain metastases; and the influence of diet on cancer development and response to therapy. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2021 AACR Annual Meeting launched week 1 of a two-week program on April 10 featuring plenary sessions and major scientific symposia. Week 2 will take place in May. In this week's podcast, The ASCO Post speaks with faculty at AACR's annual meeting who presented clinical research in non–small cell lung cancer, non-Hodgkin lymphoma, and uveal melanoma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we'll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We'll also hear about an update to the NCCN Guidelines for triple-negative breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we're again discussing findings presented during the Society of Gynecologic Oncology's (SGO) Virtual 2021 Annual Meeting on Women's Cancer. We're hearing from three presenting authors on a number of topics, including maintenance olaparib for newly diagnosed advanced ovarian cancer; maintenance niraparib for platinum-sensitive ovarian cancer; and methods for reducing radiotherapy toxicity in patients with cervical cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
The Society of Gynecologic Oncology's virtual 2021 Annual Meeting on Women's Cancer is taking place from March 19 to 25. This week, we're hearing about findings presented at the meeting in endometrial and ovarian cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts .
More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we'll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We'll also discuss two FDA approvals that occurred over the past week for lymphoma and kidney cancer. Coverage of stories discussed this week on ascopost.com: Increase in Diagnosis of Node-Positive and Stage III Breast...
This week, we're discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug's indication for small cell lung cancer. Coverage of stories discussed this week on ascopost.com: FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma FDA Approves Lorlatinib for Metastatic ALK -Positive NSCLC Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn T...
This week, we're continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2021 Genitourinary Cancers Symposium took place virtually from February 11 to 13. This week, we're hearing from three authors of novel research in bladder and kidney cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts .
